A study presented at the American Heart Association's annual scientific conference compared Pfizer's cholesterol fighting statin Lipitor with Zocor. The research found little evidence to back Pfizer's contention that aggressive dosages of Lipitor could cut heart attack rates by reducing LDL cholesterol levels. Given that Zocor goes off patent next year, this could spell bad news for Lipitor sales, which are the highest of any drug.
- see this article from the AP
ALSO: A second study led by Dr. Bruce Perler of Johns Hopkins produced rather more interesting results. Perler's team found that patients at risk of having a stroke who take statins before preventative surgery greatly reduce their chances of suffering negative outcomes. Article